Other languages Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Real-time Estimate Cboe BZX Other stock markets 15:02:25 15/05/2024 BST			5-day change	1st Jan Change
1.455 ^USD	+1.04%		-8.86%	-58.62%

05-01	Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	CI
04-24	Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	05-01
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	04-24
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-10
Sector Update: Health Care Stocks Decline Late Afternoon	03-25
Top Midday Gainers	03-25
Sector Update: Health Care Stocks Softer in Afternoon Trading	03-25
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	03-25
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	03-25
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	02-07
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	01-24
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	01-24
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules	12-29
Altamira Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders Equity Requirement	11-29
An unknown private equity investor acquired 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd..	11-20
Sector Update: Health Care Stocks Slipping Late Afternoon	11-17
Top Midday Gainers	11-17
Altamira Therapeutics to Sell 51% of Bentrio Maker for $2.3 Million	11-17
Altamira Therapeutics Ltd. Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis	14/09/23
Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	12/09/23
Altamira Therapeutics Collaborating With Pharma Nordic to Market, Distribute Bentrio Nasal Spray in Scandinavia	20/07/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Other languages

Filters